J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data

Janssen has debuted the first safety and efficacy data on Tremfya in ulcerative colitis, and so far, prospects for a label expansion look good. The readout accompanies positive 48-week results in Crohn’s disease, further solidifying Tremfya’s case in inflammatory bowel disease (IBD).